Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trial Program of a Medical Instrument Product.

Trial Profile

Clinical Trial Program of a Medical Instrument Product.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Aspirin; Bivalirudin; Clopidogrel; Heparin
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Embolism and thrombosis; Myocardial ischaemia; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms SEEDS
  • Most Recent Events

    • 01 Mar 2017 Status changed from recruiting to active, no longer recruiting, according to the results published in the Catheterization and Cardiovascular Interventions
    • 01 Mar 2017 Results of SEEDS substudy (n=1851) assessing SRI as a predictor of adverse ischemic events, published in the Catheterization and Cardiovascular Interventions
    • 07 Nov 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2010).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top